Percutaneous catheter and guidewire for filtering during ablation of myocardial or vascular tissue

Abstract

An ablation catheter system for capturing and removing necrotic tissue and thrombi generated during an ablative procedure is disclosed. The catheter typically includes an elongate member, a filtration assembly disposed within the distal region, and an ablation instrument at the distal end. Alternatively, the ablation instrument is carried on the distal end of an ablation catheter, which is disposed within a lumen of the catheter system. The catheter may further include an aspiration port and lumen. Methods of using the devices in preventing distal embolization during ablative procedures are disclosed.

Description

RELATED APPLICATIONS [0001] This application is a continuation application of U.S. patent application Ser. No. 10 / 699,727, filed Nov. 3, 2003, which is a continuation application of U.S. patent application Ser. No. 09 / 766,940, filed Jan. 22, 2001, now U.S. Pat. No. 6,673,090, which is a continuation application of U.S. patent application Ser. No. 09 / 369,060, filed Aug. 4, 1999, now U.S. Pat. No. 6,235,044.FIELD OF THE INVENTION [0002] The present invention generally relates to devices and methods useful in capturing embolic material during ablation of myocardial or vascular tissue. More specifically, the devices remove necrotic tissue debris generated during ablation of ectopic foci, e.g., in the left atrium, the right atrium, and the pulmonary vein, in patients with paroxysmal atrial fibrillation or other sustained atrial tachyarrhythmias. The devices include a trapping mechanism for capturing the necrotic tissue debris and may include aspiration capabilities. BACKGROUND OF THE INV...

AI Technical Summary

Benefits of technology

[0009] It is known that patients with drug and cardioversion refractory paroxysmal atrial fibrillation and other sustained atrial arrhythmias, e.g., atrial flutter and sustained atrial tachycardia, may benefit from catheter ablation of ectopic atrial foci. The present invention provides devices and methods which include filtering and aspiration capabilities for trapping and removing necrotic tissue debris and thrombi generated during the ablative therapy, thereby minimizing embolization to other organs.

Problems solved by technology

Atrial fibrillation is perpetuated by reentrant wavelets propagating outside the normal cardiac conduction pathway, resulting in rapid, irregular heart rate and the loss of atrioventricular synchrony.

However, disadvantages associated with anti-arrhythmic therapy are that (1) the anti-arrhythmic agents are pro-arrhythmic, e.g., causing torsades de pointe, (2) the anti-arrhythmic agents often carry significant side effects, such as lupus-like syndrome and agranulocytosis, and (3) even with two anti-arrhythmic drugs, some patients may be resistant to pharmacological therapy, e.g., patients may continue to have at least one episode of atrial fibrillation every two days or frequent isolated atrial ectopic beats (more than 700 per day).

However, thromboembolic risk is unchanged and atrial systole is not restored with these procedures.

The ablative techniques used to restore normal sinus rhythm, where the tissue surface is subjected to extreme localized temperature designed to kill cellular structures, can generate necrotic tissue fragments or blood clots.

These tissue debris or thrombi may travel downstream from the procedural site to lodge in other organs, causing stroke, myocardial infarction, renal infarcts, and tissue ischemia in other organs.

Images